<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988817</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1021-01</org_study_id>
    <nct_id>NCT02988817</nct_id>
  </id_info>
  <brief_title>Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors</brief_title>
  <official_title>First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine the maximum tolerated dose and to establish the&#xD;
      safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and&#xD;
      an expansion part (phase IIa).&#xD;
&#xD;
      The dose escalation part has two dose escalation arms: the first arm investigates a once&#xD;
      every 3 weeks (1Q3W) dosing schedule and the second arm investigates a three administrations&#xD;
      over 4 weeks (3Q4W) dosing schedule.&#xD;
&#xD;
      The Expansion part of the trial will further explore the recommended phase 2 dose and dosing&#xD;
      regimens of HuMax-AXL-ADC as determined in Part 1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Dose Limiting Toxicities will be assessed from first treatment cycle (3 or 4 weeks)</time_frame>
    <description>As this is a phase I trial the main objective is to assess the recommended phase 2 dose of enapotamab vedotin (HuMax-AXL-ADC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>At end of trial (up to 24 months)</time_frame>
    <description>As this is a phase I trial the main objective is to assess the safety and tolerability of enapotamab vedotin (HuMax-AXL-ADC) throughout the treatment periods of the patients participating in the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters, Cmax</measure>
    <time_frame>At end of trial (up to 10 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity measured by tumor shrinkage (based on computerized tomography [CT]-scan evaluations), change in Cancer Antigen (CA) 125.</measure>
    <time_frame>At end of trial (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters, AUC</measure>
    <time_frame>At end of trial (up to 10 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Enapotamab vedotin (HuMax-AXL-ADC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All arms of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enapotamab vedotin (HuMax-AXL-ADC)</intervention_name>
    <description>All arms of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC)</description>
    <arm_group_label>Enapotamab vedotin (HuMax-AXL-ADC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. For the dose escalation part: Patients with selected, relapsed solid tumors who have&#xD;
             failed available standard therapy or who are not candidates for standard therapy.&#xD;
&#xD;
          2. For the expansion part: Patients with relapsed, advanced and/or metastatic solid&#xD;
             tumors who are not candidates for standard therapy&#xD;
&#xD;
          3. Patients must have measurable disease according to Response Evaluation Criteria In&#xD;
             Solid Tumors (RECIST).&#xD;
&#xD;
          4. For the expansion patients must provide a fresh tumor biopsy at enrolment&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Acceptable renal function&#xD;
&#xD;
          7. Acceptable liver function&#xD;
&#xD;
          8. Acceptable hematological status&#xD;
&#xD;
          9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
         10. Life expectancy of at least three months.&#xD;
&#xD;
         11. Patients, both females and males, of childbearing/reproductive potential must agree to&#xD;
             use adequate contraception while included in the trial and for six months after the&#xD;
             last infusion of HuMax-AXL-ADC&#xD;
&#xD;
         12. Patients must provide a signed informed consent form before any trial relates&#xD;
             activities are carried out.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for&#xD;
             at least 4 weeks prior to first IMP administration.&#xD;
&#xD;
          2. Have clinically significant cardiac disease&#xD;
&#xD;
          3. Known congestive heart failure and/ or a known decreased cardiac ejection fraction of&#xD;
             &lt; 45%. A baseline QT interval as corrected by Fridericia's formula (QTcF) &gt; 480 msec,&#xD;
             a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left&#xD;
             bundle branch block form) or an incomplete left bundle branch block.&#xD;
&#xD;
          4. Uncontrolled hypertension&#xD;
&#xD;
          5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage&#xD;
             colony stimulating factor support 3 weeks prior to first IMP administration.&#xD;
&#xD;
          6. Have received a cumulative dose of corticosteroid ≥ 150 mg prednisone (or equivalent&#xD;
             doses of corticosteroids) within two weeks before the first Investigational Medicinal&#xD;
             Product (IMP) administration.&#xD;
&#xD;
          7. History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as&#xD;
             known or suspected allergy or intolerance to any agent given in the course of this&#xD;
             trial.&#xD;
&#xD;
          8. Major surgery within four weeks before first IMP administration.&#xD;
&#xD;
          9. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain&#xD;
             metastases or stroke.&#xD;
&#xD;
         10. Any anticancer therapy including; small molecules, immunotherapy, chemotherapy&#xD;
             monoclonal antibodies or any other experimental drug within five half-lives but&#xD;
             maximum four weeks before first infusion. Accepted exceptions are bisphosphonates,&#xD;
             denosumab and gonadotropin-releasing hormone agonist or antagonist.&#xD;
&#xD;
         11. Prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding&#xD;
             site targeting payload.&#xD;
&#xD;
         12. Radiotherapy within 14 days prior to first IMP administration.&#xD;
&#xD;
         13. Known past or current malignancy other than inclusion diagnosis, except for:&#xD;
&#xD;
               -  Cervical carcinoma of Stage 1B or less.&#xD;
&#xD;
               -  Non-invasive basal cell or squamous cell skin carcinoma.&#xD;
&#xD;
               -  Non-invasive, superficial bladder cancer.&#xD;
&#xD;
               -  Prostate cancer with a current PSA level &lt; 0.1 ng/mL.&#xD;
&#xD;
               -  Breast cancer in BRCA1 or BRCA2 positive ovarian cancer patients.&#xD;
&#xD;
               -  Any curable cancer with a complete response (CR) of &gt; 2 years duration.&#xD;
&#xD;
         14. Melanoma patients with an LDH ≥ 3 x ULN.&#xD;
&#xD;
         15. Ongoing significant, uncontrolled medical condition including:&#xD;
&#xD;
             o Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.&#xD;
&#xD;
         16. Grade 2 or higher peripheral neuropathy.&#xD;
&#xD;
         17. Clinically significant active viral, bacterial or fungal infection&#xD;
&#xD;
         18. Known human immunodeficiency virus seropositivity.&#xD;
&#xD;
         19. Known positive serology for hepatitis B (unless due to vaccination or passive&#xD;
             immunization due to immunoglobulin therapy)&#xD;
&#xD;
         20. Known positive serology for hepatitis C (unless due to immunoglobulin therapy)&#xD;
&#xD;
         21. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the trial or evaluation of the trial result&#xD;
&#xD;
         22. History of organ allograft (except for corneal transplant) or autologous or allogeneic&#xD;
             bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of&#xD;
             IMP&#xD;
&#xD;
         23. Body weight &lt; 40 kg&#xD;
&#xD;
         24. Women who are pregnant or breast feeding.&#xD;
&#xD;
         25. Pulmonary hemorrhage or hemoptysis &gt; 2.5 ml blood within 6 weeks unless cause has been&#xD;
             addressed and is medically resolved.&#xD;
&#xD;
         26. History of acute pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignace Vergote, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, Smilow Cancer Center at Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Reearch Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Roi Albert II - Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel - Oncologisch Centrum</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medische oncologie, Oncologisch Centrum - AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven Gasthuisberg, Department of General Medical Oncology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège, Medical Oncology et. Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, Medical Oncology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Cancer Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Vall D'hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Mèdica/ Medical Oncology Department Institut Catalá d'Oncologia (ICO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08909</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lozano Blesa, Aragón Health Research Institute (IIS Aragón)</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtity College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust Clinical Trials Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Clinical Trials Unit at the Northern Centre for Cancer Care, Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

